Harvard Bioscience Seeks Shareholder Approval for Reverse Stock Split to Avoid Nasdaq Delisting

summarizeSummary

Harvard Bioscience, Inc. is seeking shareholder approval for a reverse stock split, with a ratio between 1-for-5 and 1-for-15, to regain compliance with Nasdaq's minimum $1.00 bid price requirement and avoid delisting.

check_boxKey Events

• Reverse Stock Split Proposal

  Shareholders will vote on an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio of 1-for-5 to 1-for-15.

• Nasdaq Compliance Requirement

  The primary purpose of the reverse stock split is to regain compliance with Nasdaq's minimum $1.00 bid price requirement by March 30, 2026, to avoid delisting.

• Board Recommendation

  The Board of Directors unanimously recommends voting 'FOR' the reverse stock split proposal.

• Potential Risks

  The company notes that a reverse split does not guarantee a sustained increase in share price or continued Nasdaq compliance, and could lead to further value loss or reduced liquidity.

auto_awesomeAnalysis

Harvard Bioscience, Inc. is facing a critical deadline to regain compliance with Nasdaq's minimum $1.00 bid price requirement by March 30, 2026, to avoid delisting. The proposed reverse stock split, with a flexible ratio between 1-for-5 and 1-for-15, is a necessary measure to increase the per-share price and maintain its listing. While this action aims to prevent delisting, which would severely impair the company's ability to raise capital and reduce liquidity, it does not address underlying business fundamentals. The company acknowledges that a reverse split carries risks, including the possibility that the share price may not increase proportionately or be sustained, potentially leading to further value loss.